Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Area51 who wrote (5661)	12/19/2023 10:20:27 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

I really think it should have been worth substantially more and that we could either get a counter offer or have Institutions balk at the price. I'm purchasing some cheap, just out of the buyout price options in the hope I'm right. The latest results revealed that it shouldn't be that long before IMGN has a second approved drug. IMGN ought to be valued at half of what SGEN was purchased for, they're getting a fraction of that. Gary